Skip to main content
Equibles

Panna Sharma

CEO

Lantern Pharma Inc. (LTRN)

Board Member

Lantern Pharma Inc. (LTRN)

Equibles does not estimate personal net worth.

Get an email with a short summary when Lantern Pharma Inc. publishes a filing, an earnings call transcript or a press release.

Get LTRN alerts

About Panna Sharma

Panna Sharma is recorded as CEO and Board Member at Lantern Pharma Inc. (LTRN). The newest filing on record that lists Panna Sharma as CEO and Board Member at Lantern Pharma Inc. (LTRN) is dated October 19, 2026. The proxy statement of Lantern Pharma Inc. reports total compensation of $1,090,634 for Panna Sharma in fiscal 2024, including a base salary of $575,000. Disclosed compensation is on record for 6 fiscal years. Panna Sharma has spoken on 21 earnings calls and 1 other investor event across 1 company, most recently for Lantern Pharma Inc. on October 15, 2026. Lantern Pharma Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lantern Pharma Inc. includes David Margrave (CFO) and Lee T. Schalop, M.D. (Board Member).

Panna Sharma on recent calls

“Sorry to keep you guys waiting, but let's go ahead and get started.”
CEO, ThinkEquity Conference ·
“Good morning, everyone, and thank you for joining us to discuss our second quarter 2026 results.”
CEO, Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET ·
“Good afternoon, and thank you for joining us today to hear about our fourth quarter and fiscal year 2025 results in corporate progress.”
CEO, Lantern Pharma Inc. Q4 FY2025 Earnings Call ·
“Good morning, everyone, and thank you for joining us to hear about our third quarter 2025 results and corporate progress as many of you have heard me say in the past computational and ai driven approaches are increasing their presence and usage at both large and emerging pharma companies for all facets of drug…”
CEO, Lantern Pharma Inc. Q3 FY2025 Earnings Call ·
“Thank you for joining us to hear about our first quarter 2025 results and corporate progress. As many of you have heard me say in the past, computational and AI-driven approaches are increasing their presence and usage at both large and emerging pharma companies for all facets of drug discovery and development.”
CEO, Lantern Pharma Inc. Q1 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Lantern Pharma Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Lantern Pharma Inc. (LTRN) $575,000 $1,090,634
2023 Lantern Pharma Inc. (LTRN) $525,300 $684,385
2022 Lantern Pharma Inc. (LTRN) $474,580 $1,053,818
2021 Lantern Pharma Inc. (LTRN) $432,000 $622,000
2020 Lantern Pharma Inc. (LTRN) $384,492 $1,594,166
2019 Lantern Pharma Inc. (LTRN) $266,923 $331,923

Recent activity

Show 10 earlier activities